Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Myoarchitectural disarray of hypertrophic cardiomyopathy begins pre-birth.

Garcia-Canadilla P, Cook AC, Mohun TJ, Oji O, Schlossarek S, Carrier L, McKenna WJ, Moon JC, Captur G.

J Anat. 2019 Jul 26. doi: 10.1111/joa.13058. [Epub ahead of print]

PMID:
31347708
2.

Association of Asymmetric Dimethylarginine and Diastolic Dysfunction in Patients with Hypertrophic Cardiomyopathy.

Cordts K, Seelig D, Lund N, Carrier L, Böger RH, Avanesov M, Tahir E, Schwedhelm E, Patten M.

Biomolecules. 2019 Jul 13;9(7). pii: E277. doi: 10.3390/biom9070277.

3.

Analysis of Contractile Function of Permeabilized Human Hypertrophic Cardiomyopathy Multicellular Heart Tissue.

Kresin N, Stücker S, Krämer E, Flenner F, Mearini G, Münch J, Patten M, Redwood C, Carrier L, Friedrich FW.

Front Physiol. 2019 Mar 28;10:239. doi: 10.3389/fphys.2019.00239. eCollection 2019.

4.

Biallelic mutation in MYH7 and MYBPC3 leads to severe cardiomyopathy with left ventricular noncompaction phenotype.

Kolokotronis K, Kühnisch J, Klopocki E, Dartsch J, Rost S, Huculak C, Mearini G, Störk S, Carrier L, Klaassen S, Gerull B.

Hum Mutat. 2019 Aug;40(8):1101-1114. doi: 10.1002/humu.23757. Epub 2019 Apr 24.

PMID:
30924982
5.

Autophagy in cardiomyopathies.

Zech ATL, Singh SR, Schlossarek S, Carrier L.

Biochim Biophys Acta Mol Cell Res. 2019 Feb 6. pii: S0167-4889(18)30496-8. doi: 10.1016/j.bbamcr.2019.01.013. [Epub ahead of print] Review.

PMID:
30831130
6.

Making Sense of Inhibiting Nonsense in Hypertrophic Cardiomyopathy.

Carrier L.

Circulation. 2019 Feb 5;139(6):812-814. doi: 10.1161/CIRCULATIONAHA.118.037936. No abstract available.

PMID:
30715935
7.

The homozygous K280N troponin T mutation alters cross-bridge kinetics and energetics in human HCM.

Piroddi N, Witjas-Paalberends ER, Ferrara C, Ferrantini C, Vitale G, Scellini B, Wijnker PJM, Sequiera V, Dooijes D, Dos Remedios C, Schlossarek S, Leung MC, Messer A, Ward DG, Biggeri A, Tesi C, Carrier L, Redwood CS, Marston SB, van der Velden J, Poggesi C.

J Gen Physiol. 2019 Jan 7;151(1):18-29. doi: 10.1085/jgp.201812160. Epub 2018 Dec 21.

8.

Mechanistic role of the CREB-regulated transcription coactivator 1 in cardiac hypertrophy.

Morhenn K, Quentin T, Wichmann H, Steinmetz M, Prondzynski M, Söhren KD, Christ T, Geertz B, Schröder S, Schöndube FA, Hasenfuss G, Schlossarek S, Zimmermann WH, Carrier L, Eschenhagen T, Cardinaux JR, Lutz S, Oetjen E.

J Mol Cell Cardiol. 2019 Feb;127:31-43. doi: 10.1016/j.yjmcc.2018.12.001. Epub 2018 Dec 4.

PMID:
30521840
9.

Cardiomyopathy phenotypes in human-induced pluripotent stem cell-derived cardiomyocytes-a systematic review.

Eschenhagen T, Carrier L.

Pflugers Arch. 2019 May;471(5):755-768. doi: 10.1007/s00424-018-2214-0. Epub 2018 Oct 15. Review.

10.

Treatments targeting inotropy.

Maack C, Eschenhagen T, Hamdani N, Heinzel FR, Lyon AR, Manstein DJ, Metzger J, Papp Z, Tocchetti CG, Yilmaz MB, Anker SD, Balligand JL, Bauersachs J, Brutsaert D, Carrier L, Chlopicki S, Cleland JG, de Boer RA, Dietl A, Fischmeister R, Harjola VP, Heymans S, Hilfiker-Kleiner D, Holzmeister J, de Keulenaer G, Limongelli G, Linke WA, Lund LH, Masip J, Metra M, Mueller C, Pieske B, Ponikowski P, Ristic A, Ruschitzka F, Seferovic PM, Skouri H, Zimmermann WH, Mebazaa A.

Eur Heart J. 2018 Oct 8. doi: 10.1093/eurheartj/ehy600. [Epub ahead of print]

PMID:
30295807
11.

S100A4 as a Target of the E3-Ligase Asb2β and Its Effect on Engineered Heart Tissue.

Braumann S, Thottakara T, Stücker S, Reischmann-Düsener S, Krämer E, Groß J, Hirt MN, Doroudgar S, Carrier L, Friedrich FW.

Front Physiol. 2018 Sep 19;9:1292. doi: 10.3389/fphys.2018.01292. eCollection 2018.

12.

Gene therapy strategies in the treatment of hypertrophic cardiomyopathy.

Prondzynski M, Mearini G, Carrier L.

Pflugers Arch. 2019 May;471(5):807-815. doi: 10.1007/s00424-018-2173-5. Epub 2018 Jul 3. Review.

PMID:
29971600
13.

CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy.

Mosqueira D, Mannhardt I, Bhagwan JR, Lis-Slimak K, Katili P, Scott E, Hassan M, Prondzynski M, Harmer SC, Tinker A, Smith JGW, Carrier L, Williams PM, Gaffney D, Eschenhagen T, Hansen A, Denning C.

Eur Heart J. 2018 Nov 14;39(43):3879-3892. doi: 10.1093/eurheartj/ehy249.

14.

Activation of Autophagy Ameliorates Cardiomyopathy in Mybpc3-Targeted Knockin Mice.

Singh SR, Zech ATL, Geertz B, Reischmann-Düsener S, Osinska H, Prondzynski M, Krämer E, Meng Q, Redwood C, van der Velden J, Robbins J, Schlossarek S, Carrier L.

Circ Heart Fail. 2017 Oct;10(10). pii: e004140. doi: 10.1161/CIRCHEARTFAILURE.117.004140.

15.

Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model.

Stücker S, Kresin N, Carrier L, Friedrich FW.

Front Physiol. 2017 Aug 2;8:558. doi: 10.3389/fphys.2017.00558. eCollection 2017.

16.

Evaluation of MYBPC3 trans-Splicing and Gene Replacement as Therapeutic Options in Human iPSC-Derived Cardiomyocytes.

Prondzynski M, Krämer E, Laufer SD, Shibamiya A, Pless O, Flenner F, Müller OJ, Münch J, Redwood C, Hansen A, Patten M, Eschenhagen T, Mearini G, Carrier L.

Mol Ther Nucleic Acids. 2017 Jun 16;7:475-486. doi: 10.1016/j.omtn.2017.05.008. Epub 2017 May 17.

17.

Blinded Contractility Analysis in hiPSC-Cardiomyocytes in Engineered Heart Tissue Format: Comparison With Human Atrial Trabeculae.

Mannhardt I, Eder A, Dumotier B, Prondzynski M, Krämer E, Traebert M, Söhren KD, Flenner F, Stathopoulou K, Lemoine MD, Carrier L, Christ T, Eschenhagen T, Hansen A.

Toxicol Sci. 2017 Jul 1;158(1):164-175. doi: 10.1093/toxsci/kfx081.

18.

Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.

Flenner F, Geertz B, Reischmann-Düsener S, Weinberger F, Eschenhagen T, Carrier L, Friedrich FW.

J Physiol. 2017 Jun 15;595(12):3987-3999. doi: 10.1113/JP273769. Epub 2017 Feb 7.

19.
20.

The embryological basis of subclinical hypertrophic cardiomyopathy.

Captur G, Ho CY, Schlossarek S, Kerwin J, Mirabel M, Wilson R, Rosmini S, Obianyo C, Reant P, Bassett P, Cook AC, Lindsay S, McKenna WJ, Mills K, Elliott PM, Mohun TJ, Carrier L, Moon JC.

Sci Rep. 2016 Jun 21;6:27714. doi: 10.1038/srep27714.

21.

Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue.

Wijnker PJ, Friedrich FW, Dutsch A, Reischmann S, Eder A, Mannhardt I, Mearini G, Eschenhagen T, van der Velden J, Carrier L.

J Mol Cell Cardiol. 2016 Aug;97:82-92. doi: 10.1016/j.yjmcc.2016.03.003. Epub 2016 Apr 22.

PMID:
27108529
22.

Serum Matrix Metalloproteinases as Quantitative Biomarkers for Myocardial Fibrosis and Sudden Cardiac Death Risk Stratification in Patients With Hypertrophic Cardiomyopathy.

Münch J, Avanesov M, Bannas P, Säring D, Krämer E, Mearini G, Carrier L, Suling A, Lund G, Patten M.

J Card Fail. 2016 Oct;22(10):845-50. doi: 10.1016/j.cardfail.2016.03.010. Epub 2016 Mar 24.

PMID:
27018569
23.

Sleeping with technology: cognitive, affective, and technology usage predictors of sleep problems among college students.

Rosen L, Carrier LM, Miller A, Rokkum J, Ruiz A.

Sleep Health. 2016 Mar;2(1):49-56. doi: 10.1016/j.sleh.2015.11.003. Epub 2016 Jan 4.

PMID:
29073453
24.

S-glutathiolation impairs phosphoregulation and function of cardiac myosin-binding protein C in human heart failure.

Stathopoulou K, Wittig I, Heidler J, Piasecki A, Richter F, Diering S, van der Velden J, Buck F, Donzelli S, Schröder E, Wijnker PJ, Voigt N, Dobrev D, Sadayappan S, Eschenhagen T, Carrier L, Eaton P, Cuello F.

FASEB J. 2016 May;30(5):1849-64. doi: 10.1096/fj.201500048. Epub 2016 Feb 2.

25.

Selective phosphorylation of PKA targets after β-adrenergic receptor stimulation impairs myofilament function in Mybpc3-targeted HCM mouse model.

Najafi A, Sequeira V, Helmes M, Bollen IA, Goebel M, Regan JA, Carrier L, Kuster DW, Van Der Velden J.

Cardiovasc Res. 2016 May 15;110(2):200-14. doi: 10.1093/cvr/cvw026. Epub 2016 Jan 29.

PMID:
26825555
26.

Targeted Mybpc3 Knock-Out Mice with Cardiac Hypertrophy Exhibit Structural Mitral Valve Abnormalities.

Judge DP, Neamatalla H, Norris RA, Levine RA, Butcher JT, Vignier N, Kang KH, Nguyen Q, Bruneval P, Perier MC, Messas E, Jeunemaitre X, de Vlaming A, Markwald R, Carrier L, Hagège AA.

J Cardiovasc Dev Dis. 2015;2(2):48-65. Epub 2015 Apr 21.

27.

Knock-out of nexilin in mice leads to dilated cardiomyopathy and endomyocardial fibroelastosis.

Aherrahrou Z, Schlossarek S, Stoelting S, Klinger M, Geertz B, Weinberger F, Kessler T, Aherrahrou R, Moreth K, Bekeredjian R, Hrabě de Angelis M, Just S, Rottbauer W, Eschenhagen T, Schunkert H, Carrier L, Erdmann J.

Basic Res Cardiol. 2016 Jan;111(1):6. doi: 10.1007/s00395-015-0522-5. Epub 2015 Dec 10.

PMID:
26659360
28.

Ranolazine antagonizes catecholamine-induced dysfunction in isolated cardiomyocytes, but lacks long-term therapeutic effects in vivo in a mouse model of hypertrophic cardiomyopathy.

Flenner F, Friedrich FW, Ungeheuer N, Christ T, Geertz B, Reischmann S, Wagner S, Stathopoulou K, Söhren KD, Weinberger F, Schwedhelm E, Cuello F, Maier LS, Eschenhagen T, Carrier L.

Cardiovasc Res. 2016 Jan 1;109(1):90-102. doi: 10.1093/cvr/cvv247. Epub 2015 Nov 3.

PMID:
26531128
29.

PLEKHM2 mutation leads to abnormal localization of lysosomes, impaired autophagy flux and associates with recessive dilated cardiomyopathy and left ventricular noncompaction.

Muhammad E, Levitas A, Singh SR, Braiman A, Ofir R, Etzion S, Sheffield VC, Etzion Y, Carrier L, Parvari R.

Hum Mol Genet. 2015 Dec 20;24(25):7227-40. doi: 10.1093/hmg/ddv423. Epub 2015 Oct 12.

30.

Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology.

Carrier L, Mearini G, Stathopoulou K, Cuello F.

Gene. 2015 Dec 1;573(2):188-97. doi: 10.1016/j.gene.2015.09.008. Epub 2015 Sep 8. Review.

31.

The E3 ubiquitin ligase Asb2β is downregulated in a mouse model of hypertrophic cardiomyopathy and targets desmin for proteasomal degradation.

Thottakara T, Friedrich FW, Reischmann S, Braumann S, Schlossarek S, Krämer E, Juhr D, Schlüter H, van der Velden J, Münch J, Patten M, Eschenhagen T, Moog-Lutz C, Carrier L.

J Mol Cell Cardiol. 2015 Oct;87:214-24. doi: 10.1016/j.yjmcc.2015.08.020. Epub 2015 Sep 3.

PMID:
26343497
32.

I-1-deficiency negatively impacts survival in a cardiomyopathy mouse model.

Friedrich FW, Sotoud H, Geertz B, Weber S, Flenner F, Reischmann S, Eschenhagen T, Carrier L, El-Armouche A.

Int J Cardiol Heart Vasc. 2015 May 29;8:87-94. doi: 10.1016/j.ijcha.2015.05.010. eCollection 2015 Sep 1.

33.

Media and technology use predicts ill-being among children, preteens and teenagers independent of the negative health impacts of exercise and eating habits.

Rosen LD, Lim AF, Felt J, Carrier LM, Cheever NA, Lara-Ruiz JM, Mendoza JS, Rokkum J.

Comput Human Behav. 2014 Jun;35:364-375.

34.

Targets for therapy in sarcomeric cardiomyopathies.

Tardiff JC, Carrier L, Bers DM, Poggesi C, Ferrantini C, Coppini R, Maier LS, Ashrafian H, Huke S, van der Velden J.

Cardiovasc Res. 2015 Apr 1;105(4):457-70. doi: 10.1093/cvr/cvv023. Epub 2015 Jan 29. Review.

35.

Research priorities in sarcomeric cardiomyopathies.

van der Velden J, Ho CY, Tardiff JC, Olivotto I, Knollmann BC, Carrier L.

Cardiovasc Res. 2015 Apr 1;105(4):449-56. doi: 10.1093/cvr/cvv019. Epub 2015 Jan 28. Review.

36.

Animal and in silico models for the study of sarcomeric cardiomyopathies.

Duncker DJ, Bakkers J, Brundel BJ, Robbins J, Tardiff JC, Carrier L.

Cardiovasc Res. 2015 Apr 1;105(4):439-48. doi: 10.1093/cvr/cvv006. Epub 2015 Jan 18. Review.

37.

Proteasome inhibition slightly improves cardiac function in mice with hypertrophic cardiomyopathy.

Schlossarek S, Singh SR, Geertz B, Schulz H, Reischmann S, Hübner N, Carrier L.

Front Physiol. 2014 Dec 16;5:484. doi: 10.3389/fphys.2014.00484. eCollection 2014.

38.

Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice.

Mearini G, Stimpel D, Geertz B, Weinberger F, Krämer E, Schlossarek S, Mourot-Filiatre J, Stoehr A, Dutsch A, Wijnker PJ, Braren I, Katus HA, Müller OJ, Voit T, Eschenhagen T, Carrier L.

Nat Commun. 2014 Dec 2;5:5515. doi: 10.1038/ncomms6515.

PMID:
25463264
39.

Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy.

Gehmlich K, Dodd MS, Allwood JW, Kelly M, Bellahcene M, Lad HV, Stockenhuber A, Hooper C, Ashrafian H, Redwood CS, Carrier L, Dunn WB.

Mol Biosyst. 2015 Feb;11(2):564-73. doi: 10.1039/c4mb00594e.

PMID:
25437646
40.

Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes.

Tanaka A, Yuasa S, Mearini G, Egashira T, Seki T, Kodaira M, Kusumoto D, Kuroda Y, Okata S, Suzuki T, Inohara T, Arimura T, Makino S, Kimura K, Kimura A, Furukawa T, Carrier L, Node K, Fukuda K.

J Am Heart Assoc. 2014 Nov 11;3(6):e001263. doi: 10.1161/JAHA.114.001263.

41.

FHL2 expression and variants in hypertrophic cardiomyopathy.

Friedrich FW, Reischmann S, Schwalm A, Unger A, Ramanujam D, Münch J, Müller OJ, Hengstenberg C, Galve E, Charron P, Linke WA, Engelhardt S, Patten M, Richard P, van der Velden J, Eschenhagen T, Isnard R, Carrier L.

Basic Res Cardiol. 2014;109(6):451. doi: 10.1007/s00395-014-0451-8. Epub 2014 Oct 31.

42.

Sexual dimorphic response to exercise in hypertrophic cardiomyopathy-associated MYBPC3-targeted knock-in mice.

Najafi A, Schlossarek S, van Deel ED, van den Heuvel N, Güçlü A, Goebel M, Kuster DW, Carrier L, van der Velden J.

Pflugers Arch. 2015 Jun;467(6):1303-17. doi: 10.1007/s00424-014-1570-7. Epub 2014 Jul 11.

PMID:
25010737
43.

Automated analysis of contractile force and Ca2+ transients in engineered heart tissue.

Stoehr A, Neuber C, Baldauf C, Vollert I, Friedrich FW, Flenner F, Carrier L, Eder A, Schaaf S, Hirt MN, Aksehirlioglu B, Tong CW, Moretti A, Eschenhagen T, Hansen A.

Am J Physiol Heart Circ Physiol. 2014 May;306(9):H1353-63. doi: 10.1152/ajpheart.00705.2013. Epub 2014 Feb 28.

44.

Ubiquitin-proteasome system and hereditary cardiomyopathies.

Schlossarek S, Frey N, Carrier L.

J Mol Cell Cardiol. 2014 Jun;71:25-31. doi: 10.1016/j.yjmcc.2013.12.016. Epub 2013 Dec 28. Review.

45.

MYBPC3 in hypertrophic cardiomyopathy: from mutation identification to RNA-based correction.

Behrens-Gawlik V, Mearini G, Gedicke-Hornung C, Richard P, Carrier L.

Pflugers Arch. 2014 Feb;466(2):215-23. doi: 10.1007/s00424-013-1409-7. Epub 2013 Dec 12. Review.

PMID:
24337823
46.

The Media and Technology Usage and Attitudes Scale: An empirical investigation.

Rosen LD, Whaling K, Carrier LM, Cheever NA, Rokkum J.

Comput Human Behav. 2013 Nov 1;29(6):2501-2511.

47.

Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.

Stöhr A, Friedrich FW, Flenner F, Geertz B, Eder A, Schaaf S, Hirt MN, Uebeler J, Schlossarek S, Carrier L, Hansen A, Eschenhagen T.

J Mol Cell Cardiol. 2013 Oct;63:189-98. doi: 10.1016/j.yjmcc.2013.07.011. Epub 2013 Jul 26.

48.

Enhanced Ca²+ influx through cardiac L-type Ca²+ channels maintains the systolic Ca²+ transient in early cardiac atrophy induced by mechanical unloading.

Schwoerer AP, Neef S, Broichhausen I, Jacubeit J, Tiburcy M, Wagner M, Biermann D, Didié M, Vettel C, Maier LS, Zimmermann WH, Carrier L, Eschenhagen T, Volk T, El-Armouche A, Ehmke H.

Pflugers Arch. 2013 Dec;465(12):1763-73. doi: 10.1007/s00424-013-1316-y. Epub 2013 Jul 11.

49.

Repair of Mybpc3 mRNA by 5'-trans-splicing in a Mouse Model of Hypertrophic Cardiomyopathy.

Mearini G, Stimpel D, Krämer E, Geertz B, Braren I, Gedicke-Hornung C, Précigout G, Müller OJ, Katus HA, Eschenhagen T, Voit T, Garcia L, Lorain S, Carrier L.

Mol Ther Nucleic Acids. 2013 Jul 2;2:e102. doi: 10.1038/mtna.2013.31.

50.

BSE-associated prion-amyloid cardiomyopathy in primates.

Krasemann S, Mearini G, Krämer E, Wagenführ K, Schulz-Schaeffer W, Neumann M, Bodemer W, Kaup FJ, Beekes M, Carrier L, Aguzzi A, Glatzel M.

Emerg Infect Dis. 2013 Jun;19(6):985-8. doi: 10.3201/eid1906.120906.

Supplemental Content

Loading ...
Support Center